Hiragi

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)	Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, laryngeal disorder, neoplasm, otorhinolaryngologic disease, respiratory system disorder, squamous cell carcinoma	Active, not recruiting	Phase 3	2026-09-25	NCT06525220
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease	Immunoglobulin G4-Related Disease, autoimmune disease, immune system disorder	Active, not recruiting	Phase 3	2026-02-04	NCT05662241
Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis	Cerebral Small Vessel Diseases, Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, granulomatosis with polyangiitis, immune system disorder, interstitial lung disease, lung disorder, microscopic polyangiitis, necrotizing vasculitis, nervous system disorder, respiratory system disorder, skin disorder, skin vascular disease, vascular disorder, vasculitis	Recruiting	Phase 4	2025-05-04	NCT06611696

Clinical trials